#USA #New York #Class Action #Pomerantz LLP #NeoGenomics

Pomerantz Law Firm Investigates Claims on behalf of Investors in NeoGenomics, Inc.

Pomerantz LLP, a prominent law firm well-known for advocating for investors' rights, has recently announced its investigation into possible securities fraud involving NeoGenomics, Inc. (NASDAQ: NEO). This investigation arises after the company reported disappointing financial results that fell short of market expectations.

On July 29, 2025, NeoGenomics disclosed its financial performance for the second quarter of 2025, revealing revenues of $181.3 million—significantly less than what analysts anticipated. Additionally, the company reported a net loss of $45.1 million for the period. In light of these results, NeoGenomics has notably revised its 2025 revenue forecast downward to between $720 million and $726 million, a steep drop from its previous projection of approximately $753 million. Furthermore, the adjusted EBITDA, initially estimated between $55 million to $58 million, has also been lowered to an expected range of $41 million to $44 million.

In the aftermath of this announcement, NeoGenomics' stock plummeted by $1.21 per share, equating to an 18.73% decline, ultimately closing at $5.25 per share. Such a significant dip in stock value raises concerns about potential securities fraud or other unlawful business practices by the company and certain members of its executive team. As a result, Pomerantz LLP encourages investors in NeoGenomics to reach out and discuss their rights and potential claims.

The firm, established over 85 years ago by the late Abraham L. Pomerantz—known as the